TGTXTG Therapeutics, Inc.
Sign up free
Thesis

BRIUMVI nearing $1B annual revenue with SC formulation and indication expansions as the growth ceiling test

Updated 43d ago

TG Therapeutics is a commercial-stage company whose approved lead product, BRIUMVI, treats relapsing multiple sclerosis, a neurological disease not yet addressed by other anti-CD20 therapies at scale.

BRIUMVI generated $227.7M in U.S. revenue in Q2 2026 alone, putting the approved anti-CD20 therapy on a path toward $950M in full-year global sales. The thesis now pivots on whether a subcutaneous formulation and MG expansion can extend the growth curve beyond the relapsing MS base, or whether the IV-only label and maturing RRMS market cap peak share. The single meaningful risk is that subcutaneous pivotal data, expected year-end 2026 or early 2027, fails to show non-inferior exposure, stranding the convenience upgrade and blunting competitive differentiation.

Status
Intact
Conviction

Current Thesis Drivers

  • Q2 2026 U.S. revenue $227.7M, 64% YoY growth
  • ENHANCE Phase 3 met primary endpoint — dosing simplification confirmed
  • SC Phase 1 bioavailability >60% vs. IV; quarterly dosing supported by PK modeling
  • SC pivotal non-inferiority unresolved; enrollment ~75% complete at last update

What could change the thesis?

  • SC pivotal topline data: non-inferiority hit extends label, miss stalls convenience story
  • MG Phase 2 readout: durable remission opens new indication, failure limits MS-only ceiling
  • sBLA consolidated dosing: approval simplifies initiation, rejection delays label update

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

4 programs · 10 catalysts

Stress Test